Session Information
-
WCLC 2022
2022 World Conference on Lung Cancer
As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2015
All times listed are in Vienna, Austria Time, CEST (UTC+2:00)
PL - Plenary
IBS - Interactive Breakfast Session (in-person attendees only)
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
P - Posters
EP - ePosters
WS - Workshops
LA – Lectureship Awards
IS - Industry Symposium
August 5 Fri
Aug 5 Saturday
August 6 Sat
Aug 6 Sunday
August 7 Sun
Aug 7 Monday
August 8 Mon
Aug 8 Tuesday
August 9 Tue
Aug 9
-
+
P1.11 - Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy
- 17:00 - 19:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: Regular Poster
- Track: Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy
-
+
P1.11-01 - Cobolimab With Dostarlimab and Docetaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC): COSTAR Lung
Presenter: Hye Ryun Kim- Abstract
Loading... -
+
P1.11-02 - Combined Regimen of Anlotinib and Trametinib for NSCLC Patients Harbouring Pan-KRAS Mutation without KRASG12C
Presenter: Baohui Han- Abstract
Loading...
-
+
P1.12 - Management of Lung Cancer in the Era of COVID-19
- 17:00 - 19:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: Regular Poster
- Track: Management of Lung Cancer in the Era of COVID-19
-
+
P1.12-01 - Lung Cancer Screening in the COVID-19 Era: Understanding Program-Level Impact
Presenter: Andrew Ciupek- Abstract
Loading... -
+
P1.12-02 - The Impact of COVID-19 on Quality of Care for Lung Cancer - Analyses of Prospective Clinical Data from The EnRICH Cohort
Presenter: Bea Brown- Abstract
Loading... -
+
P1.12-03 - Computed Tomography-based Artificial Intelligence System in the Diagnosis of COVID-19
Presenter: Yusuf Kahya- Abstract
Loading... -
+
P1.12-04 - The FLARE score and circulating neutrophils are associated with poor Covid-19 outcomes in patients with thoracic cancers
Presenter: Laura Mezquita- Abstract
Loading... -
+
P1.12-05 - Prediction of Clinically Significant Pathological Upstaging in Resected Lung Cancer: Insight from COVID-19 Pandemic (1st wave)
Presenter: Yu Zhi Zhang- Abstract
Loading...
-
+
P1.13 - Mesothelioma, Thymoma, and Other Thoracic Malignancies - Clinical
- 17:00 - 19:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: Regular Poster
- Track: Mesothelioma, Thymoma, and Other Thoracic Malignancies - Clinical
-
+
P1.13-01 - Preoperative Chemotherapy Induces Epithelial-Mesenchymal Transition Which Reduces Survival After Surgery for Mesothelioma
Presenter: Luigi Ventura- Abstract
Loading... -
+
P1.13-02 - Quantitative Assessment Using MR in Malignant Pleural Mesothelioma
Presenter: Ritu Gill- Abstract
Loading...
-
+
P1.14 - Mesothelioma, Thymoma, and Other Thoracic Malignancies - Preclinical
- 17:00 - 19:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: Regular Poster
- Track: Mesothelioma, Thymoma, and Other Thoracic Malignancies - Preclinical
-
+
P1.14-01 - Transcriptomic Analysis of Malignant Pleural Mesothelioma (MPM) Reveals Insights for Basic Research and Preclinical Testing
Presenter: Alexander Laure- Abstract
Loading... -
+
P1.14-02 - Implantable Cytokine Factories for Eradication of Malignant Pleural Mesothelioma (MPM) Tumors in Mice
Presenter: Amanda Nash- Abstract
Loading... -
+
P1.14-03 - Characterization of Tumor Immune Microenvironment and Its Prognostic Value in Patients with Surgically Resected Thymic Epithelial Tumors
Presenter: HaoJie Si- Abstract
Loading... -
+
P1.14-04 - Silencing ADAR1 Abrogates Mesothelioma Tumorigenicity
Presenter: Robert Kratzke- Abstract
Loading... -
+
P1.14-05 - TROP2 Expression and SN38 Antitumor Activity in Malignant Pleural Mesothelioma Cells
Presenter: Luca Hegedüs- Abstract
Loading...
-
+
P1.15 - Metastatic Non-small Cell Lung Cancer - Immunotherapy
- 17:00 - 19:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: Regular Poster
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
-
+
P1.15-01 - Differential Diagnosis of Pneumonitis in Metastatic NSCLC (Non-Small Cell Lung Cancer) Patients Receiving Immunotherapy With Radiomics
Presenter: Alberto Traverso- Abstract
Loading... -
+
P1.15-02 - Plasma microRNAs Modulation in Advanced NSCLC Patients Receiving Single Agent Immune Checkpoint Inhibitors
Presenter: Claudia Proto- Abstract
Loading... -
+
P1.15-03 - Clinical Outcomes Among Patients With Non-small Cell Lung Cancer Who Discontinued Immune Checkpoint Inhibitors Due to Toxicity
Presenter: Federica Pecci- Abstract
Loading... -
+
P1.15-04 - Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer
Presenter: Giulia Mazzaschi- Abstract
Loading... -
+
P1.15-05 - Nintedanib in Combination with Nivolumab in Pretreated Patients with Advanced Adenocarcinoma of the Lung (AIO-TRK-0117 Phase IB/II Trial)
Presenter: Martin Reck- Abstract
Loading... -
+
P1.15-06 - Immune-Checkpoint Inhibitors-Related Colitis in Advanced Non-small Cell Lung Cancer Patients: A Real-World Analysis
Presenter: Martina Lorenzi- Abstract
Loading... -
+
P1.15-07 - Phase II Study of Pembrolizumab and Itacitinib for First Line Treatment of Metastatic NSCLC Expressing PD-L1
Presenter: Melina Elpi Marmarelis- Abstract
Loading... -
+
P1.15-08 - Phase 1: IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy as Monotherapy or in Combination with Atezolizumab, in Adults with Non-Small Cell Lung Cancer
Presenter: Michael Boyer- Abstract
Loading... -
+
P1.15-09 - First-line Atezolizumab plus Bevacizumab for Metastatic High-Intermediate TMB in Non-squamous NSCLC. The TELMA Study.
Presenter: Mariano Provencio- Abstract
Loading... -
+
P1.15-10 - Chronic Obstructive Pulmonary Disease Patients Receiving Immunotherapy for Lung Cancer: A Population-Based Study in Canada
Presenter: Sze Wah Samuel Chan- Abstract
Loading... -
+
P1.15-11 - Durvalumab + Olaparib vs Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: Outcomes from the Phase 2 ORION Study
Presenter: Myung-Ju Ahn- Abstract
Loading... -
+
P1.15-12 - Patient-reported Outcomes of Cemiplimab versus Chemotherapy in Advanced NSCLC: PD-L1 Level Subgroups in EMPOWER-Lung 1
Presenter: Saadettin Kilickap- Abstract
Loading... -
+
P1.15-13 - Immune Escape Mechanisms Mediated by B-Catenin in Non-small Cell Lung Cancer
Presenter: Satoshi Muto- Abstract
Loading...
-
+
P1.16 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- 17:00 - 19:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: Regular Poster
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
-
+
P1.16-01 - Amivantamab and Lazertinib in Treatment-Naive EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Presenter: Byoung Chul Cho- Abstract
Loading... -
+
P1.16-02 - Clinical Utility of ctDNA in Advanced NSCLC at Diagnosis or Where Insufficient Tissue Was Available, Based on the ESMO ESCAT Scale
Presenter: Laura Mezquita- Abstract
Loading... -
+
P1.16-03 - Managing Cardiotoxicity in Metastatic Non-Small Cell Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors (TKIs)
Presenter: Luis Raez, MD, FACP, FCCP- Abstract
Loading... -
+
P1.16-04 - Phase 3 EVOKE-01 Study of Sacituzumab Govitecan vs Docetaxel in NSCLC After Prior Platinum and Checkpoint Inhibitors
Presenter: Niels Reinmuth- Abstract
Loading...